2-(4-chlorobenzyl)-1,2,3,4-tetrahydroisoquinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 2-(4-chlorobenzyl)-1,2,3,4-tetrahydroisoquinoline
• 英文别名: 2-[(4-chlorophenyl)methyl]-3,4-dihydro-1H-isoquinoline
• 化学式: C₁₆H₁₆ClN
• 分子量: 257.763
• InChiKey: ZXLRSCHFXFKVSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  四氢异喹啉 、 4-氯氯苄 以 乙腈 为溶剂， 以97%的产率得到2-(4-chlorobenzyl)-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  Designing analogs of ticlopidine, a wall teichoic acid inhibitor, to avoid formation of its oxidative metabolites

  摘要：

  The thienopyridine antiplatelet agent, ticlopidine and its analog, clopidogrel, have been shown to potentiate the action of beta-lactam antibiotics, reversing the methicillin-resistance phenotype of methicillin- resistant Staphylococcus aureus (MRSA), in vitro. Interestingly, these thienopyridines inhibit the action of TarO, the first enzyme in the synthesis of wall teichoic acid, an important cell wall polymer in Gram-positive bacteria. In the human body, both ticlopidine and clopidogrel undergo a rapid P450-dependent oxidation into their respective antiplatelet-active metabolites, resulting in very low plasma concentrations of intact drug. Herein, a series of analogs of ticlopidine and clopidogrel that would avoid oxidative metabolism were designed, prepared and evaluated as inhibitors of TarO. Specifically, we replaced the P450-labile thiophene ring of ticlopidine and clopidogrel to a more stable phenyl group to generate 2-(2-chlorobenzyl)-1,2,3,4-tetrahydro-isoquinoline) (6) and (2-chloro-phenyl)-(3,4-dihydro-1H-isoquinolin- 2-yl)-acetic acid methyl ester (22), respectively. The latter molecules displayed inhibitory activity against TarO and formed the basis of a library of analogs. Most synthesized compounds exhibited comparable efficacy to ticlopidine and clopidogrel. So far, it was introduction of a trifluoromethyl group to compound 6, to generate 2-(2-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-isoquinoline (13) that exhibited enhanced activity against TarO. Compound 13 represents a novel stable inhibitor of TarO with synergistic impact on b-lactam antibiotics against MRSA and low potential for P-450 metabolism. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.069

文献信息

• Efficient Synthesis of <i>N</i>-Alkyl Tetrahydroisoquinolines by Reductive Amination
  作者：Sukanta Bhattacharyya、Hephzibah Kumpaty

  DOI：10.1055/s-2005-872081

  日期：——

  An expedient access to diverse N-alkyl 1,2,3,4-tetrahydroisoquinolines is reported by reductive amination of aldehydes and ketones with tetrahydroisoquinoline (THIQ) in the presence of Ti(Oi-Pr) 4 and NaBH 4 . The N-alkyl THIQ products were rapidly purified by flow-through catch and release technique using commercially available polymer-supported sulfonic acid, MP-TsOH columns.

  据报道，在 Ti(Oi-Pr) 4 和 NaBH 4 存在下，用四氢异喹啉 (THIQ) 对醛和酮进行还原胺化，可以方便地获得多种 N-烷基 1,2,3,4-四氢异喹啉。N-烷基 THIQ 产品通过流通捕​​获和释放技术使用市售的聚合物负载磺酸 MP-TsOH 柱快速纯化。
• Direct β-C(sp³)–H Functionalization of Aliphatic Amines to α,β-Unsaturated Imines, Aldehydes, and Chromenes
  作者：Sumana Mandal、Sujit Mahato、Chandan K. Jana

  DOI：10.1021/acs.orglett.5b01744

  日期：2015.8.7

  functionalization of aliphatic amine was developed. The method is based on a reaction that yields enamine directly from the corresponding aliphatic amine, which otherwise requires the aid of metallic reagent and/or external oxidant. The reaction is operationally simple, general, and highly efficient in functionalizing both cyclic and acyclic amines. Structurally diverse unsaturated imines were obtained from N-heterocycles

  开发了一种无金属的脂肪胺直接β-C（sp 3）-H官能化方法。该方法基于直接从相应的脂族胺产生烯胺的反应，否则该反应需要金属试剂和/或外部氧化剂的帮助。该反应操作简单，通用，并且在官能化环状和非环状胺方面都非常有效。从N-杂环获得结构多样的不饱和亚胺，而无环胺则提供具有出色E / Z-选择性的2-烷基肉桂醛和苯并吡喃衍生物。
• NOVEL ANTIBACTERIAL COMBINATION THERAPY
  申请人：Brown Eric D.

  公开号：US20140088069A1

  公开（公告）日：2014-03-27

  An antibacterial composition is provided including a combination of a β-lactam antibiotic that has a binding affinity for bacterial penicillin-binding protein 2; and a non-antibiotic compound which may be a thienopyridine or a non-thienopyridine compound. A method of treatment using the composition is also provided.
• [EN] NOVEL ANTIBACTERIAL COMBINATION THERAPY<br/>[FR] NOUVEAU TRAITEMENT COMBINÉ ANTIBACTÉRIEN
  申请人：UNIV MCMASTER

  公开号：WO2012162814A1

  公开（公告）日：2012-12-06

  An antibacterial composition is provided including a combination of a β-lactam antibiotic that has a binding affinity for bacterial penicillin-binding protein 2; and a non-antibiotic compound which may be a thienopyridine or a non-thienopyridine compound. A method of treatment using the composition is also provided.
• Designing analogs of ticlopidine, a wall teichoic acid inhibitor, to avoid formation of its oxidative metabolites
  作者：Maya A. Farha、Kalinka Koteva、Robert T. Gale、Edward W. Sewell、Gerard D. Wright、Eric D. Brown

  DOI：10.1016/j.bmcl.2013.12.069

  日期：2014.2

  The thienopyridine antiplatelet agent, ticlopidine and its analog, clopidogrel, have been shown to potentiate the action of beta-lactam antibiotics, reversing the methicillin-resistance phenotype of methicillin- resistant Staphylococcus aureus (MRSA), in vitro. Interestingly, these thienopyridines inhibit the action of TarO, the first enzyme in the synthesis of wall teichoic acid, an important cell wall polymer in Gram-positive bacteria. In the human body, both ticlopidine and clopidogrel undergo a rapid P450-dependent oxidation into their respective antiplatelet-active metabolites, resulting in very low plasma concentrations of intact drug. Herein, a series of analogs of ticlopidine and clopidogrel that would avoid oxidative metabolism were designed, prepared and evaluated as inhibitors of TarO. Specifically, we replaced the P450-labile thiophene ring of ticlopidine and clopidogrel to a more stable phenyl group to generate 2-(2-chlorobenzyl)-1,2,3,4-tetrahydro-isoquinoline) (6) and (2-chloro-phenyl)-(3,4-dihydro-1H-isoquinolin- 2-yl)-acetic acid methyl ester (22), respectively. The latter molecules displayed inhibitory activity against TarO and formed the basis of a library of analogs. Most synthesized compounds exhibited comparable efficacy to ticlopidine and clopidogrel. So far, it was introduction of a trifluoromethyl group to compound 6, to generate 2-(2-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-isoquinoline (13) that exhibited enhanced activity against TarO. Compound 13 represents a novel stable inhibitor of TarO with synergistic impact on b-lactam antibiotics against MRSA and low potential for P-450 metabolism. (C) 2013 Elsevier Ltd. All rights reserved.